Participation in a clinical trial is one possible option for people who have cancer. It is recommended that patients talk with their doctor to discuss potential participation in a clinical trial.
Tocagen initiated a Phase 1b clinical trial in July 2016 for patients with metastatic colorectal, pancreatic, breast, lung, melanoma and renal cancers.
The trial will evaluate the safety, presence of Toca 511 genes in tumors of patients with widely disseminated disease, immunologic activity in blood and tumor and clinical activity such as tumor response and clinical benefit. Tocagen also plans, in this clinical trial, to evaluate Toca 511 & Toca FC in combination with one or more checkpoint inhibitors.